ORCID
- Upton, Mathew: 0000-0003-4287-6396
Abstract
Bacteriocin-like inhibitory substances (BLISs) that are produced by various species of Staphylococcus spp., could have potential as topical therapeutic agents for treating highly drug-resistant staphylococcal infections. The spectrum of activity of some such agents, recently identified in our laboratory, has been characterized. This was carried out at different temperatures using deferred antaonism assay. The biological activity of 221, which produced by S. epidermidis strain 221 and shows activity against Epidemic MRSA-15 and strains of MSSA, is described in detail. The initial characterization of this agent showed that its activity is stable on plates pre-exposed to high temperatures (70-80oC/30-40mins) and displaying specificity for S. aureus. This suggests that BLIS 221 is a bacteriocin in nature, possibly of Class-I.
DOI
10.15406/jmen.2017.05.00152
Publication Date
2017-07-24
Publication Title
Journal of Microbiology & Experimentation
Volume
5
Issue
3
ISSN
2373-437X
Embargo Period
2021-03-25
Organisational Unit
School of Biomedical Sciences
Recommended Citation
Mahrous, M., Burnie, J., Tagg, J., & Upton, M. (2017) 'Purification and Characterization of 221, the Cationic Peptide that Inhibits Staphylococcus aureus', Journal of Microbiology & Experimentation, 5(3). Available at: https://doi.org/10.15406/jmen.2017.05.00152
